Gilbert Block, MD, PhD

Gilbert A. Block, MD, PhD, has more than 23 years of pharmaceutical and biotechnology experience encompassing all aspects of clinical development and translational medicine; focusing primarily on neurosciences.

Dr Block is the founder and principal of The Willmatt Group, LLC. He is a member of the external review boards for FastForward LLC (a division of the National MS Society), the T1 Catalyst Translational Medicine Program at UC San Francisco, the NIH TRND group, the NINDS NeuroNext group, the NIH BriDGS program, and interim Chief Medical Officer of Neuraltus Pharmaceuticals. He is also an adjunct full professor of pharmacology and physiology at Drexel University School of Medicine.

Dr Block has extensive global leadership experience, having led groups as large as 50 people, with direct responsibility for budgets in excess of $60 million US dollars. Additionally, he has overseen, evaluated and developed licensing strategies in partnership with commercial, venture capital investors and scientific colleagues.
Previously, he was the Senior Director and Head of Clinical Neurology and Neuropharmacology at Merck and Co. Research Laboratories, Clinical Section Head of Global Neuroscience Development at AstraZeneca, Vice President of Neuroscience and Clinical Pharmacology at Cephalon, Vice President of Clinical Development at Cambridge Neurosciences, and Vice President and Global Head of Neurosciences and Clinical Training Assessments at i3 Global.

Dr. Block received his BA, PhD and MD at Case Western Reserve University. He completed his neurology residency and fellowship in cerebrovascular disease/cerebral metabolism at New York Hospital-Cornell University Medical College in New York, New York.